Professor of Surgery, University VA School of Medicine
General Surgery
Dr. Craig L. Slingluff Jr., MD
|
|
Give Review
Craig L. Slingluff Jr., MD practices General Surgery. He studied medicine at University of Virginia School of Medicine. He over the years received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACS)". Craig Slingluff is a published doctor and has 78 publications published. The lastest was: 'A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous...'
Publications
- A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous...
- A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.
- Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye.
- TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.
- Utility of sentinel lymph node biopsy for solitary dermal melanomas.
- Recent developments in the implementation of novel designs for early-phase combination studies.
- Total body photography for skin cancer screening.
- MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer.
- Erratum to: Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.
- Immunolabeling for p16, WT1, and Fli-1 in the Assignment of Growth Phase for Cutaneous Melanomas.
- Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma.
- Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.
- Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and Cutaneous Lymphocyte Antigen expression by tumor antigen-specific CD8 T cells.
- T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins.
- Design, Development, and Evaluation of a Novel Retraction Device for Gallbladder Extraction During Laparoscopic Cholecystectomy.
- Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.
- A Randomized Phase II Trial of Multi-epitope Vaccination withMelanoma Peptides for Cytotoxic T-Cells and Helper T-Cells forPatients with Metastatic Melanoma (E1602).
- A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence.
- Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial (CTEP 7190/ Mel47).
- Surgical Management of the Patient with Metastatic Melanoma to the Heart.
- Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial.
- Infrared thermography of cutaneous melanoma metastases.
- Research incentive program for clinical surgical faculty associated with increases in research productivity.
- Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.
- Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences.
- The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides.
- Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.
- Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from US Cooperative Oncology Groups.
- The present and future of Peptide vaccines for cancer: single or multiple, long or short, alone or in combination?
- Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials.
- Surgical resection for bulky or recurrent axillary metastatic melanoma.
- Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine.
- Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
- Regional control and morbidity after superficial groin dissection in melanoma.
- Intraoperative imaging guidance for sentinel node biopsy in melanoma using a mobile gamma camera.
- VEGFR-2 expression in human melanoma: Revised assessment.
- Two patients with Hailey-Hailey disease, multiple primary melanomas, and other cancers.
- Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
- A triangular intermuscular space sentinel node in melanoma: association with axillary lymphatic drainage.
- Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
- Interface of signal transduction inhibition and immunotherapy in melanoma.
- Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter r...
- Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera.
- Patients with Merkel cell carcinoma tumors < or = 1.0 cm in diameter are unlikely to harbor regional lymph node metastasis.
- Neonatal congenital malignant melanoma with lymph node metastasis.
- Resident research forums stimulate novel research within general surgical training programs.
- Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines.
- Skin mapping with punch biopsies for defining margins in melanoma: when you don't know how far to go.
- Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
- Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2.
- A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
- The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
- Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
- Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.
- Peptide and dendritic cell vaccines.
- Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
- Immunity to melanoma antigens: from self-tolerance to immunotherapy.
- Impact of patient distance to radiation therapy on mastectomy use in early-stage breast cancer patients.
- Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
- Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
- Progress and controversies in developing cancer vaccines.
- MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and a...
- Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a dela...
- Competition among peptides in melanoma vaccines for binding to MHC molecules.
- CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.
- Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.
- Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
- Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.
- Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
- Genomic organization, incidence, and localization of the SPAN-x family of cancer-testis antigens in melanoma tumors and cell lines.
- Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimul...
- Lymphoscintigraphy and sentinel node biopsy accurately stage melanoma in patients presenting after wide local excision.
- MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.
- Sentinel node biopsy in vulvar and vaginal melanoma: presentation of six cases and a literature review.
- Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.
- Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.
Schools
Virginia Commonwealth University School Of Medicine
Duke University Mc
Duke University
University Of Virginia
Procedures Preformed
- Lymph Node Dissection for Endometrial Cancer (Uterine Cancer)
Doctors Specialties
- General Surgery
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACS)
Education
-
Duke University Hospital -
University of Virginia School of Medicine
Hospital
-
University of Virginia Medical Center
Helpful Reviews
Similar Doctors
|
Dr. David Brenin, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Daniel G. Maluf, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard D. Jackson II, MD |
|
|
Dr. Jenalee N. Coster, MD |
|
|
Dr. Nicholas L. Bandy, MD |
|
|
Dr. Alex D. Michaels, MD |
|
|
Dr. Troy L. Shell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Basil W. Schaheen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan M. Sackier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Ravi K. Balireddy, MB BS |